



Volta Medical's RESTART Trial Shows Promising Findings for AI Solutions in Recurrent Atrial Fibrillation

Descrizione

COMUNICATO STAMPA • CONTENUTO PROMOZIONALE

MARSEILLE, France, Feb. 3, 2026 /PRNewswire/ • Volta Medical, committed to revolutionizing care for underserved complex AF patients with breakthrough AI solutions, announced results from the RESTART trial, published in Heart Rhythm. This study demonstrates positive outcomes for patients with recurrent AF and isolated pulmonary veins who underwent ablation using Volta's AI solution for spatio-temporal dispersion mapping, a population who has historically had suboptimal outcomes. 1,2 Findings from the trial will be presented at AF Symposium on Thursday February 5, 2026, at 8:30am ET in Boston, MA by principal investigator Dr. John Hummel MD, FHRS, Director of Electrophysiology at the Ohio State University Wexner Medical Center.

The RESTART trial was an interventional, prospective, single-arm, multicenter clinical trial. Patients with previous catheter or surgical ablation for AF were enrolled. Patients with documented reconnected pulmonary veins during the procedure were prospectively withdrawn from the trial. Follow-up included 3-6- and 12-month visits. The primary endpoint of the study was freedom from documented AF at 12-months after a single AI-guided repeat ablation procedure.

The RESTART trial (NCT05477147) is the first prospective, multicenter study to evaluate this innovative approach. Key findings include:

You can access the full publication here: [https://www.heartrhythmjournal.com/article/S1547-5271\(26\)00105-0/abstract](https://www.heartrhythmjournal.com/article/S1547-5271(26)00105-0/abstract)

• Patients with recurrent atrial fibrillation and isolated pulmonary veins represent one of the most frustrating populations we treat. Many of these patients have already undergone multiple procedures and are told there are no good options left,• said Dr. John Hummel. • The RESTART trial shows the potential of Volta's AI solution. •

“With more than 7 million people living with atrial fibrillation in the US today, the need for better treatment options has never been greater,” said Th  ophile Mohr-Durdez, CEO and co-founder of Volta Medical. “The RESTART trial reinforces the potential of our AI solution to transform AF care. We are proud to lead the way in delivering innovative solutions that address critical gaps in care for some of the most complex cases.”

The RESTART trial involved one of the most challenging patient populations in atrial fibrillation care, individuals with recurrent AF despite confirmed durable pulmonary vein isolation.^{1,2} These patients have historically faced poor success rates with empirical strategies.^{1,2} By leveraging Volta Medical’s AI solution, RESTART demonstrates that even in this highly complex group, personalized, data-driven therapy has the potential to deliver improved outcomes.

About Atrial Fibrillation

The American Heart Association (AHA) defines atrial fibrillation (AF) as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.⁵ It is estimated that 7 million patients in the US are living with AF.^{4,5} Even though untreated AF doubles the risk of heart-related deaths and is associated with a 5-fold increased risk for stroke, many patients are unaware that AF is a serious condition.

About Volta Medical

Volta Medical is a health technology company advancing the use of AI to transform the treatment of complex cardiac arrhythmias. Founded in 2016 in Marseille, France, by three physicians and a data scientist, Volta’s mission is to improve outcomes for patients with AF by developing cutting-edge, data-driven solutions trained on vast procedural datasets.

The company’s flagship product, AF-Xplorer   II, is a next-generation digital AI companion designed to assist electrophysiologists with the real-time identification of spatio-temporal dispersed electrograms (EGMs) during AF and atrial tachycardia procedures. Engineered for versatility, AF-Xplorer II integrates seamlessly with leading AF mapping and recording systems and is compatible with the most common ablation modalities. The solution is both U.S. FDA 510(k) cleared and European CE Marked.

To support awareness and education, Volta Medical created the AI for Persistent AF Care program to connect patients, caregivers, and providers with resources about AF and AI-guided treatment. For more information, visit www.aiforafib.com.

Media Contact Molly Megna, Sr. Marketing Manager molly.megna@volta-medical.com

References

Logo     https://mma.prnewswire.com/media/2659428/VoltaMedical_Logo.jpg

View original content: <https://www.prnewswire.co.uk/news-releases/volta-medicals-restart-trial-shows-promising-findings-for-ai-solutions-in-recurrent-atrial-fibrillation-302676841.html>

Copyright 2026 PR Newswire. All Rights Reserved.

COMUNICATO STAMPA - CONTENUTO PROMOZIONALE: Immediapress - un servizio di diffusione di comunicati stampa in testo originale redatto direttamente dall'ente che lo emette. L'Adnkronos e Immediapress non sono responsabili per i contenuti dei comunicati trasmessi

[immediapress/pr-newswire](#)

Categoria

1. Comunicati

Tag

1. ImmediaPress

Data di creazione

Febbraio 3, 2026

Autore

redazione

default watermark